Gao, Jingtao
Gao, Mengqiu
Du, Jian
Pang, Yu
Mao, Gary
Lounis, Nacer
Bakare, Nyasha
Jiang, Yanxin
Zhan, Ying
Liu, Yuhong http://orcid.org/0000-0002-3769-6852
Li, Liang
Rongmei, Liu
Juan, Du
Guihui, Wu
Yi, Pei
Wei, Sha
Lian, Shi
Hua, Wang
Long, Jin
Yuqing, Wu
Yu, Xiong
Xiaofeng, Yan
Xiaohong, Chen
Zhongfeng, Huang
Fei, Ren
Xiujie, Li
Huiru, An
Junwei, Cui
,
Funding for this research was provided by:
Janssen China Research and Development Center
Article History
Received: 1 October 2023
Accepted: 18 January 2024
First Online: 1 April 2024
Declarations
:
: The ICF, study protocol, investigator brochures, eCRF, and investigator qualifications have been submitted and approved by EC of Beijing Chest Hospital, Capital Medical University as the leading center (The NO. is 2022–04), all of which have been approved by REC/IRB at each participating medical facility as well. The study was not started until the written approval was obtained. Written, informed consent to participate is requested from all participants.
: Not applicable.
: GJT, GMQ, DJ, PY, LYH, ZY, and LL declare that they have no competing interests. GM, NL, NB, and JYX are employees of Janssen participating in the development of bedaquiline.